Frank Rimerman Advisors’s Royalty Pharma RPRX Stock Holding History

Frank Rimerman Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$612K	Hold	10,493	–	–	0.03%	362
2026 Q2	$588K	Hold	10,493	–	–	0.03%	372
2026 Q1	$503K	Hold	10,493	–	–	0.03%	375
2025 Q4	$405K	Sell	10,493 -19	-0.2%	-$725	0.03%	431
2025 Q3	$371K	Buy	10,512 +57	+0.5%	+$2.06K	0.02%	430
2025 Q2	$377K	Buy	10,455 +3,863	+59%	+$128K	0.03%	399
2025 Q1	$205K	Buy	+6,592	New	+$209K	0.02%	496

Other funds holding RPRX

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $53.6B AUM 32.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Fideuram Asset Management (Ireland) Dublin 1 $4.57B AUM 30.36% 1-Year Est. Return

Todd Asset Management Louisville, Kentucky $5.51B AUM 33.77% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Frank Rimerman Advisors's RPRX Position: Q3 2026 in Review

Frank Rimerman Advisors held its Royalty Pharma (RPRX) position steady in Q3 2026 at 10,493 shares worth $612K. The position accounts for 0.03% of the portfolio, ranked #362.

Frank Rimerman Advisors first reported a position in RPRX in Q1 2025 and has held it in 7 quarters since. 193 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

Frank Rimerman Advisors held 10,493 shares of Royalty Pharma worth $612K as of Q3 2026.
Frank Rimerman Advisors left its Royalty Pharma share count unchanged in Q3 2026.
Royalty Pharma made up 0.03% of Frank Rimerman Advisors's portfolio in Q3 2026, its #362 holding.
Frank Rimerman Advisors first reported a position in Royalty Pharma in Q1 2025 and has held it in 7 quarters since.
193 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Frank Rimerman Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.